DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Tilray
Tilray
Pioneering the Future of Global Cannabis June 2020
Tilray Inc - Class 2 Annual Report 2021
Tilray Annual Report 2020
Vote for the Business Combination of Aphria And
Tilray & Aphria Announce Closing of Transaction That Creates the “New
Growing Hemp for Grain Lamont County 2020 Outline • Hemp Food Industry Overview • Market Trends • Quality • Agronomy • Economics
Dear Aphria Shareholders, Vote for the Business Combination of Aphria and Tilray to Create the Ote Largest Global Cannabis Company
Legalized Medical Cannabis
In the Court of Chancery of the State of Delaware in Re
Tilray: Next in Line in a Budding Cannabis Industry Target Price of $45/Share
Tilray Acquires Majority Position in Amended Medmen Convertible Notes
What Providers Should Know About Patients Using Cannabis Carol Freedman Rph, BCGP Objectives
BCP Research: Aphria (APHACN)/ Tilray (TLRY): Thoughts on Merger- Maintain APHACN 24S ‘Swap Positive’, Upgrade TLRY 23S to ‘Outright Positive’
Cannabis Practice Group
Growing the Evidence Base for Medical Cannabis
UBC and Tilray Partner for Canada's First PTSD Cannabis Study
Tilray: Global Leader
Tilray® to Acquire Manitoba Harvest, the World's Largest Hemp Food
Top View
Medical Cannabis & PTSD;
APRIL 2021 UNLOCKING the ENDOCANNABINOID SYSTEM NEWSLETTER - April 2021
Tilray Commences Trading on the Toronto Stock Exchange Under Symbol “TLRY”
Leading the Global Cannabis Industry
New Zealand Approves Launch of Tilray™S Medical Cannabis Products
Cannabis Industry Continues to Roll
Project Earth Closing Press Release 1042Pm ET Vfinal.Docx
Tilray® Receives Approvals to Expand and Commercialize Medical Cannabis Products in New Zealand
Tilray® Forms Strategic Alliance with Leading Pharmaceutical Company in Canada
Aphria and Tilray Investor Presentation December 2020
In the United States District Court for the District of Delaware
Tilray Inc. (TLRY)
Herbal Cannabis and Pharmaceutical Cannabinoid Treatment Following Motor Vehicle Accidents: a State of the Science Review
TITLE: Medical Marijuana for Post-Traumatic Stress Disorder: a Review of Clinical Effectiveness and Guidelines DATE: 11 January
Tilray Inc. 2018 Annual Report
Post-Traumatic Stress Disorder (PTSD) AUGUST 2016
Tilray, Inc. Form 8-K/A Current Event Report Filed 2021-07-30
TILRAY, INC. (Exact Name of Registrant As Specified in Its Charter)
Tilray Inc - Class 2 Annual Report 2021
Tilray® Signs Global Collaboration Agreement with Leading Pharmaceutical Company
Cannabis Industry 2020 Year-In-Review February 2021
Evolve Marijuana Fund MACROECONOMIC HIGHLIGHTS
Tilray Launches New Medical Cannabis Edibles in Canada
Dear Aphria Shareholders, Vote for the Business Combination of Aphria and Tilray to Create the Ote Largest Global Cannabis Company
Pioneering the Future of Global Cannabis January 2020
Cannabis Industry Outlook Research and Education
Demystifying Medical Cannabis
NYU School of Medicine Will Lead Trials Testing CBD Treatment for Patients with Alcohol Use Disorder and Post-Traumatic Stress Disorder with Alcohol Use Disorder
Pioneering the Future of Global Cannabis November 2018
The Long-Term, Prospective, Therapeutic Impact of Cannabis on Post-Traumatic Stress Disorder
Aphria to Host Special Meeting of Shareholders on Wednesday, April 14, 2021 to Approve Proposed Aphria-Tilray Business Combination
UBC and Tilray Launch Canada's First Clinical Trial to Study Medical Cannabis and PTSD
Tilray, Inc. Annual Report 2019
Grown by Batch Released by Product Name Variety Or Cultivar Approx
Aphria Inc. Reminds Shareholders to Vote to Approve Proposed Aphria-Tilray Business Combination